Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Oxabact in dialysis patients with primary hyperoxaluria
2013-004368-74Phase 2Completed
- Sponsor
- OxThera AB
- Start
- Nov 2013
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxalobacter formigenes in Primary hyperoxaluria (PH), sponsored by OxThera AB. Primary endpoint: Change in total plasma oxalate. Started Nov 2013; status: completed.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on 2013-004368-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004368-74.